Trials / Active Not Recruiting
Active Not RecruitingNCT05701774
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Willi Syndrome
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 83 (estimated)
- Sponsor
- Soleno Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 4 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DCCR | Once daily oral administration |
Timeline
- Start date
- 2023-01-31
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2023-01-27
- Last updated
- 2025-04-02
Locations
22 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05701774. Inclusion in this directory is not an endorsement.